Sanofi SA (ADR) news

   Watch this stock
Showing stories 11 - 20 of about 227   

Articles published

SNY 47.42 -0.94 (-1.94%)
price chart
Sanofi SA (ADR) (NYSE:SNY) Ties Up With Voyager For $845M Gene Therapy
Genzyme, a subsidiary of Sanofi SA (ADR) (NYSE:SNY), is partnering with upstart Voyager Therapeutics, which focuses on gene therapy development.
Whistleblower Lawsuit Accuses Sanofi SA (SNY), Ousted CEO Of Kickback ...
Sanofi SA (ADR) (NYSE:SNY) has found itself caught in a whistleblower lawsuit, where a former employee is accusing the company of funneling $34 million in kickbacks and incentive payments to various doctors and pharmacies, influencing them to prescribe ...
Related articles »  
Has Sanofi SA (ADR) (NYSE:SNY) Fallen Enough?
Sanofi's diabetes franchise appears to be in trouble, with its drug Lantus facing increased competition. The company has projected flat sales for its diabetes offerings, in great part due to increased generic competition when Lantus loses its patent ...
Despite Myriad Of Issues, Sanofi Might Be A Good Buy  Seeking Alpha
Sanofi SA (ADR) (SNY) And Netflix, Inc. (NFLX) Executives Entangled In ...
When Sanofi SA (ADR) (NYSE:SNY) CEO Christopher Viehbacher was sacked recently, it was believed that the disagreement between him and the board was the reason of his unfortunate exit.
Sanofi SA (SNY) Continues Search For Head; Smith & Nephew (SNN) CEO Out ...
In an employee meeting, Smith & Nephew plc (ADR) (NYSE:SNN) Chief Executive Olivier Bohuon dismissed rumors of his plans to leave the medical-device maker to join Sanofi SA (ADR) (NYSE:SNY), as per reports from Bloomberg. This implies that Sanofi, ...
Related articles »  
Sanofi SA (SNY) Outsources Research Facility To Evotec (EVTCY)
Sanofi SA (ADR) (NYSE:SNY) is reportedly in exclusive talks with Hamburg-based Evotec AG (ADR) (OTCMKTS:EVTCY) to transfer its research operations in Toulouse, France to the German drug-maker.
Related articles »  
Sanofi Fires CEO Following Clash With Board
Sanofi SA (ADR) (SNY) announced today that the company's board has decided to oust Chief Executive Officer Christopher Viehbacher, finally putting the rumors to rest.
Related articles »  
Sanofi SA (ADR) (SNY) Trading at Discount to Fair Value
�What it really all came down to, last quarter they reported disappointing guidance for their diabetes franchise, and probably even more importantly what affected the stock was that the CEO was fired due to conflicts with the board of directors of the ...
Sanofi SA (SNY) Gets FDA Nod For Priftin Tablets To Treat Latent TB Infection
Sanofi SA (ADR) (NYSE:SNY) announced before US markets opened for trading Tuesday that the US Food and Drug Administration (FDA) has approved its Priftin (rifapentine) tablets for the treatment of latent tuberculosis infection.
Related articles »  
Sanofi SA (SNY), Regeneron Pharmaceuticals (REGN) Eczema Drug Gets FDA ...
Sanofi SA (ADR) (NYSE:SNY) and its US-based partner Regeneron Pharmaceuticals Inc's (NASDAQ:REGN) jointly developed experimental drug dupilumab has been granted breakthrough therapy designation by the US Food and Drug Administration for use ...
Related articles »